Results

RDF/XMLNTriplesTurtleShow queryShare ▶
SubjectPredicateObject
http://purl.uniprot.org/citations/34863919http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/34863919http://www.w3.org/2000/01/rdf-schema#comment"

Objectives

Benznidazole is the first-line treatment for Chagas disease. Adverse events appear in more than 50% of patients, leading to discontinuation in approximately 15%. Cutaneous reactions are one of the most frequent adverse events. Human leucocyte antigen (HLA) genotyping studies identified an association between cutaneous reactions to benznidazole and carrying the specific allele HLA-B∗35:05. We designed the present study to prospectively confirm this association.

Methods

This is a prospective observational study including Chagas disease patients aged 18 years or more who accepted to receive benznidazole treatment following current guidelines. Allele genotyping of HLA-B was determined in all patients. Clinical and analytical follow up was performed at days 0, 7, 14, 30 and 60 of treatment.

Results

Two-hundred and seven individuals were included. Seventy per cent were female with a mean age of 45.1 (SD ± 9.86) years mainly from Bolivia (92.8%). In 102 (49.3%) cases a cutaneous reaction was diagnosed. Forty-eight (46.6%) were classified as mild, 37 (35.9%) as moderate and 18 (17.5%) as severe. Thirty-two (15.4%) patients had to definitively interrupt the treatment because of a cutaneous reaction. Female sex (OR 4.49; 95% CI 1.62-12.47), new-onset eosinophilia before cutaneous symptoms (OR 2.55; 95% CI 1.2-5.43) and carrying the HLA-B∗35 allelic group (OR 2.58; 95% CI 1.2-5.51) were all predictors of moderate to severe cutaneous reactions. No statistical significance was found when the specific allele HLA-B∗35:05 was analysed.

Conclusions

Patients carrying the HLA-B∗35 allelic group are at higher risk of moderate to severe reactions when taking benznidazole treatment."xsd:string
http://purl.uniprot.org/citations/34863919http://purl.org/dc/terms/identifier"doi:10.1016/j.cmi.2021.11.021"xsd:string
http://purl.uniprot.org/citations/34863919http://purl.uniprot.org/core/author"Molina I."xsd:string
http://purl.uniprot.org/citations/34863919http://purl.uniprot.org/core/author"Roure S."xsd:string
http://purl.uniprot.org/citations/34863919http://purl.uniprot.org/core/author"Salvador F."xsd:string
http://purl.uniprot.org/citations/34863919http://purl.uniprot.org/core/author"Franco-Jarava C."xsd:string
http://purl.uniprot.org/citations/34863919http://purl.uniprot.org/core/author"Sulleiro E."xsd:string
http://purl.uniprot.org/citations/34863919http://purl.uniprot.org/core/author"Pou D."xsd:string
http://purl.uniprot.org/citations/34863919http://purl.uniprot.org/core/author"Trevino B."xsd:string
http://purl.uniprot.org/citations/34863919http://purl.uniprot.org/core/author"Valerio L."xsd:string
http://purl.uniprot.org/citations/34863919http://purl.uniprot.org/core/author"Bosch-Nicolau P."xsd:string
http://purl.uniprot.org/citations/34863919http://purl.uniprot.org/core/author"Arrese-Munoz I."xsd:string
http://purl.uniprot.org/citations/34863919http://purl.uniprot.org/core/author"Aznar M.L."xsd:string
http://purl.uniprot.org/citations/34863919http://purl.uniprot.org/core/author"Espinosa-Pereiro J."xsd:string
http://purl.uniprot.org/citations/34863919http://purl.uniprot.org/core/author"Oliveira-Souto I."xsd:string
http://purl.uniprot.org/citations/34863919http://purl.uniprot.org/core/author"Sanchez-Montalva A."xsd:string
http://purl.uniprot.org/citations/34863919http://purl.uniprot.org/core/author"Serre-Delcor N."xsd:string
http://purl.uniprot.org/citations/34863919http://purl.uniprot.org/core/date"2022"xsd:gYear
http://purl.uniprot.org/citations/34863919http://purl.uniprot.org/core/name"Clin Microbiol Infect"xsd:string
http://purl.uniprot.org/citations/34863919http://purl.uniprot.org/core/pages"881.e1-881.e5"xsd:string
http://purl.uniprot.org/citations/34863919http://purl.uniprot.org/core/title"Association of HLA-B∗35 and moderate or severe cutaneous reactions secondary to benznidazole treatment in chronic chagas disease."xsd:string
http://purl.uniprot.org/citations/34863919http://purl.uniprot.org/core/volume"28"xsd:string
http://purl.uniprot.org/citations/34863919http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/34863919
http://purl.uniprot.org/citations/34863919http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/34863919
▶